Develop partnerships that expand the precompetitive space through clinical proof of concept mechanism to accelerate translational learning and to fill critical knowledge gaps in understanding the network biology of drug targets and drug-target interactions.
- Establish at least one precompetitive partnership to validate the therapeutic targets that will be delivered by the Accelerating Medicines Partnership for AD (AMP-AD), as well as other pioneer targets, through clinical proof of mechanism/proof of concept.
- Research Implementation Area
- Public Private Partnerships
- To Be Initiated